

12-27-05

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/010942-Conf. #5594
		Filing Date	December 6, 2001
		First Named Inventor	Guriq BASI
		Art Unit	1647
		Examiner Name	C. J. Nichols
Total Number of Pages in This Submission		Attorney Docket Number	ELN-002

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Debra J. Milasincic		
Date	December 22, 2005	Reg. No.	46,931



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
JAMES E. COCKFIELD (1930-2005)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DEBRA J. MILASINCIC, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
HATHAWAY P. RUSSELL *
MARIA LACOTRIPE ZACHARAKIS, Ph.D.
DANIELLE L. HERRITT

EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
JAMES M. MCKENZIE
JILL R. GORNY
SAPNA MEHTANI, Ph.D.
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
LAURA C. DILORENZO

PATENT AGENTS
CRISTIN HOWLEY COWLES, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA
BRIAN C. TRINQUE, Ph.D.

TECHNICAL SPECIALISTS
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
MEAGHAN L. RICHMOND, Ph.D.
SHARON M. WALKER, Ph.D.
ALISSA H. FARIS
SEAN R. MacDAVITT

* Admitted in TX only
** Admitted in CT only

December 22, 2005

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/010,942
For: *HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE*
Inventors: Gur iq Basi *et al.*
Filed: December 6, 2001
Our Ref. No.: ELN-002

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO SB/08B;
3. PTO/SB/21;
4. Fee Transmittal
5. Copies of references cited in PTO Form PTO/SB/08B (65 references); and
6. A Return Postcard.

Please charge \$180.00 to our Deposit Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Express Mail Label No. EV 418604498 US

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants

BEST AVAILABLE COPY



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2005

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

<i>Complete if Known</i>	
Application Number	10/010942-Conf. #5594
Filing Date	December 6, 2001
First Named Inventor	Guriq BASI
Examiner Name	C. J. Nichols
Group Art Unit	1647
Attorney Docket No.	ELN-002

METHOD OF PAYMENT (check all that apply)

Check CREDIT CARD MONEY ORDER OTHER NONE

Deposit Account

Deposit Account Number 12-0080

Deposit Account Name Lahive & Cockfield, LLP

The Commissioner is hereby authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge – late filing fee or oath	
1052	50	2052	25	Surcharge – late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	REQUESTING PUBLICATION OF SIR AFTER	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)		1806		Submission of an Information Disclosure Statement	180.00


*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

**or number previously paid, if greater. For Reissues, see above

SUBMITTED BY		<i>Complete (if applicable)</i>		
Name (Print/Type)	Debra J. Milasincic	Registration No. (Attorney/Agent)	46,931	Telephone (617) 227-7400
Signature			Date	December 22, 2005

Express Mail Label No. EV 418604498 US Dated: December 22, 2005



Express Mail Label No. EV 418604498 US

Dated: December 22, 2005

Docket No.: ELN-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guriq Basi *et al.*

Application No.: 10/010942

Confirmation No.: 5594

Filed: December 6, 2001

Art Unit: 1649

For: HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE

Examiner: K. A. Ballard

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant(s) and their Attorney are aware of the following publications, listed on the attached PTO Form SB/08, and in accordance with 37 CFR 1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;

12/30/2005 DTESEM1 00000003 120080 10010942

01 FC:1806

180.00 DA

10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
10/934,609 filed 09/02/04 issued as U.S. 6,946,135 on 09/20/2005;
10/933,559 filed 09/02/04 issue fee paid 01/24/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04 issue fee paid 01/24/05;
10/815,404 filed 03/31/04 issue fee paid 11/12/04;
10/884,892 filed 07/01/04 issued as U.S. 6,962,707 on 11/08/05
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00 issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;

09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,929 filed 11/28/00;
09/724,567 filed 11/28/00 issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00 issue fee paid 02/10/05;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);
issued as U.S. 6,913,745 on 07/05/05; and,
09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 02/27/04;
10/232,030 filed 08/30/02;
10/010,942 filed 12/06/01;
10/388,389 filed 03/12/03;

10/703,713 filed 11/07/03;
10/704,070 filed 11/07/03;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04.
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/251,892 filed 12/06/00;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99; and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;

60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant(s) understand(s) that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Dated: December 22, 2005

Respectfully submitted,

By _____

Debra J. Milasincic
Registration No.: 46,931
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/010,942
Sheet	1	of	6	Filing Date	December 6, 2001
				First Named Inventor	Guriq Basi, et al.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly A.
				Attorney Docket Number	ELN-002

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	658	6,905,686	06-14-2005	Schenk	
	659	6,890,535	05-10-2005	Schenk	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	583	2004/0265919 A1	12-30-2004	Vanderstichle et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	675	6,710,226	02-23-2004	Schenk	
	584	5,589,154	12-31-1996	Anderson	
	644	5,618,920	04-08-1997	Robinson et al.	
	643	5,693,762	12-02-1997	Queen et al.	
	642	5,702,906	12-30-1997	Rosenthal	
	646	4,816,567	03-28-2989	Cabilly et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	647	4,816,397	03-28-1989	Boss et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	587	JP	7-165799	A	06-27-1995		abst. only

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

	632	JP	7-132033	A	05-23-1995			abst. only
	631	JP	62-267297	A	11-19-1987			abst. only
	585	WO	04/080419	A2	09-23-2004			
	586	WO	03/077858	A2, A3	09-25-2003			
	633	WO	96/08565	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
	648	WO	91/09967	A1	07-11-1991			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	591	CHROMY et al., "Self-assembly of Aβ(1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40-amino acid forms of amyloid-β protein are generated from the β-amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	
	594	DEMATTOS et al., "Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <i>Science</i> , 295(5563):2264-2267 (2002).	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.

Attorney Docket Number

ELN-002

595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).
596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).
597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).
598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).
599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).
600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).
650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).
601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).
602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).
603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).
604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).
605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).
606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).
664	HARLOW et al., eds., <u>Antibodies: A Laboratory Manual</u> , pages 71-82 (1998).
607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002).
662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

608	IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001).	
609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001).	
640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46:336-348 (1996).	
628	KOFLER et al. "Mechanism of allergic cross-reactions—III. cDNA cloning and variable-region sequence analysis of two IgE antibodies specific for trinitrophenyl." <u>Mol Immunol.</u> , 29(2):161-6 (1992).	
635	KOFLER et al. "IgE antibody light chain (VJ) [Mus musculus]." GenBank Accession No. CAA46659. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1870480 on August 26, 2005.	
636	KOFLER et al. "M.musculus DNA for IgE antibody light chain (VJ)." GenBank Accession No. X65775. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=312078 on August 26, 2005.	
627	KRISHNAN et al., "Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies." <u>J Immunol.</u> , 157(6):2430-9 (1996).	
634	KRISHNAN et al. "anti-DNA immunoglobulin light chain IgG [Mus musculus]." Genbank Accession No. AAB488000. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1870480 on 08-26-2005.	
651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , pages 1748-1754 (2001).	
665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).	
666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).	
610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	
611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60284284 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.

Attorney Docket Number ELN-002

	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
	653	PAUL, W. E., eds., <u>Fundamental Immunology</u> , Third Edition, pages 292-295, Raven Press, New York (1993).	
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti- $A\beta$ immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	655	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news , pages 1-5 (2002).	
	629	SEIDL, K.J. et al. "Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites." <u>Proc Natl Acad Sci U S A</u> , 96(5):2262-7 (1999).	
	637	SEIDL, K.J. et al. "immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]." GenBank Accession No. AAD26773. Retrieved from the internet at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=4633434 on August 26, 2005.	
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60284284 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

O I P E 449B
DEC 22 2005
P A T E N T & T R A D E M A R K O F F I C E

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	10/010,942
Filing Date	December 6, 2001
First Named Inventor	Guriq Basi, et al.
Art Unit	1649
Examiner Name	Ballard, Kimberly A.
Attorney Docket Number	ELN-002

619	SIGURDSSON et al., "Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice," <u>Am. J. Pathol.</u> , 159(2):439-447 (2001).	
620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β-amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	
623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
676	<i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988).	
625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60284284 v1